Motivation:
This survey is the result of a large study upon related
subjects to adjuvant therapy for multiple sclerosis (MS). It exposes no
miracle
cures and the word "adjuvant" should be noted, implying the need for
other therapy (e.g., high dose interferon-beta) as the primary, more
important
treatment. In the following pages, various items are exposed for your
survey.
The main motivation for publishing this review in the Internet is to
save you
from spending the time I utilized myself: why should other people start
from
the beginning again?
Language: It
is the English I write without any editing. For the purpose of being
understood, I hope my writing suffices. The level should be
academically and it
should not be considered popular literature. Besides, literature
abstracts can
speak for themselves.
Content:
(actual/planned/possible)
Last
revision:
Comprehensive
terminology and abbreviations (currently missing)
The
Jungle Model,
"good" and "bad" cells & humoral factors
(currently missing)
Factors
primarily acting against destruction of the blood brain barrier:
Glucocorticoids
(uncertain,
currently missing)
Matrix-Metalloproteinase-Inhibitors
Minocycline
and
other old drugs revisited
Factors
directed against oxidant destruction:
Amino acids, vitamins
and trace
elements
Jan. 25,
2002
Unspecific
immune
manipulation
Intravenous
immuneglobulins (uncertain,
currently
missing)
Glatimer racemate (Copaxone,
Copolymer-1)
Jan. 25,
2002
Oral
tolerance (uncertain,
currently
missing)
Other
approaches
Mercury
Clearance and d-Penicillamin
Jan. 6,
2009
Transforming growth
factor beta
Apr. 4,
2001
July 21,
2001
Nov. 7,
2001
Remyelinization (currently missing,
incuding the realistic clinical approach)
Studying
the matter
June 10,
2004
MS-Science
2004:
Nihilism and nonethical studies prevail
Feb. 29,
2004
A future MS-register?
(natural
history of
MS)
Are
anaesthetists
at particular risk of developing MS?
Links
to other MS-sources (currently missing)
Conclusion
MS-Therapy - a
holoistic approach
MS-Therapy
- an alternative approach
Nov.
17,
2002
Last
revision July 28